Albumedix

@Albumedix

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery

Copenhagen, Denmark
Vrijeme pridruživanja: siječanj 2016.

Tweetovi

Blokirali ste korisnika/cu @Albumedix

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Albumedix

  1. 8. ožu 2017.

    Our CSO, Darrell Sleep, talks and how to utilize their full potential with

    Poništi
  2. proslijedio/la je Tweet
    17. ožu 2016.

    Nottingham-based Medical Technology firm Albumedix could help people living with haemophilia

    Poništi
  3. 15. ožu 2016.

    VELTIS drug delivery technology used by to achieve 14 day dosing for IDELVION haemophilia B therapy

    Poništi
  4. 1. ožu 2016.

    Find out more about the world's first engineered abumin for optimized half-life

    Poništi
  5. 29. velj 2016.

    Fantastic piece on our commercialization agreement with ThioLogics by Dan Stanton

    Poništi
  6. proslijedio/la je Tweet
    23. velj 2016.

    Tomorrow we’ll be discussing Next-Generation Drug Conjugates

    Poništi
  7. 23. velj 2016.

    Dave Mead & Darrell Sleep talk next-gen drug conjugates at tomorrow's innovation day. Who's registered?

    Poništi
  8. 22. velj 2016.

    is increasing. Our Veltis technology can improve quality of life for millions of patients worldwide

    Poništi
  9. 18. velj 2016.

    If you're exploring optimized routes for stable drug conjugation, the Innovation Day is for you

    Poništi
  10. proslijedio/la je Tweet
    16. velj 2016.

    Albumedix announces exclusive commercialization agreement with ThioLogics for proprietary drug conjugation platform

    Poništi
  11. proslijedio/la je Tweet

    New Agreement for 's Conjugation Platform

    Poništi
  12. 16. velj 2016.

    Looking to learn more about advances in the development of conjugation chemistries?

    Poništi
  13. proslijedio/la je Tweet
    16. velj 2016.

    Albumedix Announces Exclusive Commercialization Agreement with ThioLogics via

    Poništi
  14. 16. velj 2016.

    Thrilled to announce an exclusive commercialization agreement with ThioLogics for its drug conjugation platform

    Poništi
  15. 11. velj 2016.

    Interested in the vastly evolving field of drug conjugates? Join our experts at the innovation day

    Poništi
  16. 10. velj 2016.

    Acquires Eleven Biotherapeutics' Supermin® Albumin Variant Technology

    Poništi
  17. 9. velj 2016.

    Hear our scientists present at the 'Next-Generation Drug Conjugates' event taking place on 24 February

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·